The Effect of HbA
HbA1c variability
coefficient of variation of HbA1c
diabetic retinopathy
severity of diabetic retinopathy
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
24 Jun 2021
24 Jun 2021
Historique:
received:
16
05
2021
revised:
09
06
2021
accepted:
22
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
To measure the relationship between variability in HbA A prospective case-series study, was conducted on 366 Type 1 Diabetes Mellitus patients with normoalbuminuria and without diabetic retinopathy at inclusion. The cohort was followed for a period of 12 years. The Cox survival analysis was used for the multivariate statistical study. The effect of variability in microangiopathy (retinopathy and nephropathy) was evaluated by calculating the standard deviation of HbA A total of 106 patients developed diabetic retinopathy (29%) and 73 microalbuminuria (19.9%). Overt diabetic nephropathy, by our definition, affected only five patients (1.36%). Statistical results show that the current age, mean HbA By measuring the variability in HbA
Sections du résumé
BACKGROUND
BACKGROUND
To measure the relationship between variability in HbA
METHODS
METHODS
A prospective case-series study, was conducted on 366 Type 1 Diabetes Mellitus patients with normoalbuminuria and without diabetic retinopathy at inclusion. The cohort was followed for a period of 12 years. The Cox survival analysis was used for the multivariate statistical study. The effect of variability in microangiopathy (retinopathy and nephropathy) was evaluated by calculating the standard deviation of HbA
RESULTS
RESULTS
A total of 106 patients developed diabetic retinopathy (29%) and 73 microalbuminuria (19.9%). Overt diabetic nephropathy, by our definition, affected only five patients (1.36%). Statistical results show that the current age, mean HbA
CONCLUSIONS
CONCLUSIONS
By measuring the variability in HbA
Identifiants
pubmed: 34202444
pii: diagnostics11071151
doi: 10.3390/diagnostics11071151
pmc: PMC8304596
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Instituto de Salud Carlos III
ID : PI18/00169
Références
J Hypertens. 2005 Mar;23(3):505-11
pubmed: 15716690
PLoS One. 2014 Mar 07;9(3):e91137
pubmed: 24609115
Ophthalmology. 2003 Sep;110(9):1677-82
pubmed: 13129861
Diabetes. 2015 Feb;64(2):631-42
pubmed: 25204977
J Diabetes Complications. 2012 Nov-Dec;26(6):506-12
pubmed: 22921286
Acta Ophthalmol. 2018 Aug;96(5):459-464
pubmed: 30188024
Br J Ophthalmol. 2016 Oct;100(10):1366-71
pubmed: 26769672
Lancet Neurol. 2010 May;9(5):469-80
pubmed: 20227347
Diabet Med. 1999 Mar;16(3):253-66
pubmed: 10227573
Acta Diabetol. 2013 Jun;50(3):437-42
pubmed: 23417155
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
Diabetes Res Clin Pract. 2010 Jan;87(1):4-14
pubmed: 19896746
Diabetologia. 2013 Apr;56(4):737-45
pubmed: 23314044
Lancet. 2010 Mar 13;375(9718):895-905
pubmed: 20226988
Diabet Med. 2012 Dec;29(12):1562-6
pubmed: 22913483
Diabetes Res Clin Pract. 2017 Jun;128:15-23
pubmed: 28432895
Endokrynol Pol. 2014;65(2):83-9
pubmed: 24802730
J Diabetes Res. 2018 Feb 26;2018:5637130
pubmed: 29682579
Am J Ophthalmol. 2005 Oct;140(4):667-73
pubmed: 16083842
Diabetes. 2009 Nov;58(11):2649-55
pubmed: 19651819
Diabetes Care. 2020 Jan;43(Suppl 1):S66-S76
pubmed: 31862749
Diabetologia. 2007 Oct;50(10):2042-3
pubmed: 17712546
Br J Ophthalmol. 2017 Oct;101(10):1346-1351
pubmed: 28270484
Diabetes Care. 2012 Mar;35(3):556-64
pubmed: 22301125
Diabetes Care. 2008 Nov;31(11):2198-202
pubmed: 18650371
Diabetes Metab. 2008 Dec;34(6 Pt 1):612-6
pubmed: 18824382
Diabetes Care. 2006 Jul;29(7):1486-90
pubmed: 16801566
Diabetes Care. 2011 Apr;34(4):1011-3
pubmed: 21335371
Lancet Glob Health. 2017 Dec;5(12):e1221-e1234
pubmed: 29032195